It looks like Glaxo has agreed to buy $129.4 M more of Theravance stock - perhaps to further prop up its partner on drugs like Relovair, an asthma treatment. GSK will now own 19% with this development.
Posted by Bruce Lehr November 29th 2010.
TrackBack URL for this entry:
Listed below are links to weblogs that reference Glaxo Buys $129M in Theravance Stock:
The comments to this entry are closed.